Study of the Effects of ITCA 650 on Gastric Emptying and Interaction of ITCA 650 on 4 Commonly Studied Drugs

A Phase 1, Fixed-Sequence, Open-label Study in Healthy Subjects to Estimate the Effects of ITCA 650 on Gastric Emptying and on the Absorption Pharmacokinetics of Each of 4 Commonly Studied Drug/Drug Interaction (DDI) Probe Compounds

A Phase 1, Fixed-Sequence, Open-label Study in Healthy Subjects to Estimate the Effects of ITCA 650 on Gastric Emptying and on the Absorption Pharmacokinetics of Each of 4 Commonly Studied DDI Probe Compounds.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Drug: ITCA 650 20/60 mcg/day; Drug: Acetaminophen; Drug: Atorvastatin; Drug: Lisinopril; Drug: Warfarin; Drug: Digoxin

Detailed Description

Acetaminophen will be use to assess the effect of ITCA 650 on the rate of gastric emptying.

Interactions between ITCA 650 and the medications lisinopril, digoxin, atorvastatin, and warfarin will also be studied.

• Study Type: Interventional
• Enrollment (Actual): 33
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Kansas
    • Overland Park, Kansas, United States, 66211
      • Quintiles

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Body mass index (BMI) between 19 to 32 kg/m2.
• Glycosylated hemoglobin A1c (HbA1c )<6.5%.
• Normal renal function (eGFR ≥80 mL/min/1.73 m2).
• Women of child bearing potential - use of an additional adequate method of contraception during the study and until 1 additional menstrual cycle following the end-of-study (EOS) visit. Adequate methods of contraception for women of child bearing potential (WOCBP) include: mechanical products (ie, intrauterine device [IUD]-copper IUD); or barrier methods (eg, diaphragm, condoms, cervical cap) with spermicide.

Exclusion Criteria:

• History of type 1 or type 2 diabetes.
• History or evidence of myocardial infarction, coronary revascularization (coronary artery bypass grafting or percutaneous coronary intervention), unstable angina, or cerebrovascular accident or stroke.
• History of uncontrolled hypertension.
• History or evidence of acute or chronic pancreatitis.
• History of liver disease.
• History of medullary thyroid cancer or a personal or family history of multiple endocrine neoplasia type 2.
• Poor thyroid, liver, or renal function.
• Weight loss surgery or requires weight loss medications.
• History of malignancy (not including basal or squamous cell carcinoma of the skin with past 5 years). (Subjects who have been disease free for 5 years may be included.)
• History of active alcohol or substance abuse.
• Weekly consumption of more than 7 alcoholic beverages for females and 14 alcoholic beverages for males.
• Excessive in xanthine consumption (more than 5 cups of coffee or equivalent per day).
• Treatment with medications that affect GI motility.
• Any condition that would affect drug transit time or absorption (eg, gastrointestinal bypass surgery, partial or total gastrectomy, small bowel resection, chronic diarrhea, vagotomy, chronic gastroesophageal reflux disease, malabsorption, colostomy, Crohn's disease, ulcerative colitis, or celiac sprue).
• History of hypersensitivity to exenatide.
• Contraindications or warnings according to the specific label(s) for acetaminophen, atorvastatin, lisinopril, digoxin or warfarin therapy.
• Women that are pregnant, lactating, or planning to become pregnant.
• Concurrent use of anticoagulants, including daily low dose aspirin (81 mg).
• History of or positive results on screening tests for hepatitis B and/or hepatitis C and/or human immunodeficiency virus (HIV).
• Planned in-patient surgery, dental procedure, or hospitalization during the study.
• Prior or current treatment with any glucagon-like peptide-1 (GLP-1) receptor agonist (eg, Bydureon™, Byetta®, Victoza®, Tanzeum® or exogenous native GLP-1) or prior participation in an ITCA 650 clinical trial.
• Use or intended use of any drug or other product that inhibits or induces cytochrome P450 (CYP)1A2, CYP2C9, CYP2C19, or CYP3A4 within 14 days prior to the first dose of warfarin or ITCA650 or during the conduct of the study.
• History of thrombophlebitis, thromboembolic disorders, or deep vein thrombophlebitis.
• Fasting triglycerides above upper limit of normal at Screening.
• Any gastrointestinal complaints within 7 days prior to first dosing.
• Taking drugs or natural herbal supplements (such as albuterol, antacids, and St. John's Wort) with known interactions with atorvastatin, lisinopril, digoxin, or warfarin from within 7 days prior to Day 1 until EOS
• Consumed or unwilling to refrain from grapefruit, cranberries, grapefruit- or cranberry-containing products, or Seville oranges from within 7 days prior to Day 1 until EOS.
• Chronic use of analgesics, pain medication, or non-steroidal anti-inflammatory agents.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Experimental Treatment; ITCA 650 20/60 mcg/day Acetaminophen 1000 mg Atorvastatin 40 mg Lisinopril 20 mg Warfarin 25 mg Digoxin 0.5 mg

Drug: ITCA 650 20/60 mcg/day; ITCA 650 osmotic mini pump delivering exenatide 20 mcg/day for 14 days, followed by ITCA 650 osmotic mini pump delivering exenatide 60 mcg/day.; Drug: Acetaminophen; Oral acetaminophen 1000 mg on Day 1 and Day 27; Drug: Atorvastatin; Oral atorvastatin 40 mg on Day 2 and Day 28; Drug: Lisinopril; Oral lisinopril 20 mg on Day 2 and Day 28; Drug: Warfarin; Oral warfarin 25 mg on Day 2 and Day 28; Drug: Digoxin; Oral digoxin 0.5 mg on Day 2 and Day 28

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Area under the concentration-time curve from time zero to the last measurable concentration [AUC(0-last)]) of acetaminophen alone and in the presence of ITCA 650.	time zero to 10 weeks
Maximum plasma concentration ([Cmax]) of acetaminophen alone and in the presence of ITCA 650	time zero to 10 weeks
Area under the concentration-time curve (AUC(0-last)) of atorvastatin, lisinopril, digoxin, R-warfarin, and S-warfarin each alone and in the presence of ITCA 650.	time zero to 10 weeks
Cmax of atorvastatin, lisinopril, digoxin, R-warfarin, and S-warfarin each alone and in the presence of ITCA 650.	time zero to 10 weeks

Secondary Outcome Measures

Outcome Measure	Time Frame
Time to maximum plasma concentration (tmax) of acetaminophen	time zero to 10 weeks
tmax of atorvastatin, lisinopril, digoxin, R warfarin, and S-warfarin	time zero to 10 weeks
AUC(0-last) of orthohydroxy-atorvastatin and parahydroxy-atorvastatin	time zero to 10 weeks
Cmax of orthohydroxy-atorvastatin and parahydroxy-atorvastatin	time zero to 10 weeks
Maximum effect (Emax)from time zero to the last measurable concentration (AUEC(0-last)) of international normalized ratio (INR) of warfarin.	time zero to 10 weeks
Cmax of ITCA 650, 20 mcg/d and 60 mcg/d	within 8 hours after placement of ITCA 650
Treatment-emergent adverse events (TEAEs) including any events local to the placement site, clinical laboratory measurements, ECGs, vital signs and physical examinations.	time zero to 10 weeks
Tmax of orthohydroxy-atorvastatin and parahydroxy-atorvastatin	time zero to 10 weeks
Cmin of ITCA 650, 20 mcg/d and 60 mcg/d	time zero to 10 weeks
Tmax of ITCA 650, 20 mcg/d and 60 mcg/d	time zero to 10 weeks
Tmin of ITCA 650, 20 mcg/d and 60 mcg/d	zero to 10 weeks
Time of maximum effect (tEmax)from time zero to the last measurable concentration (AUEC(0-last)) of international normalized ratio (INR) of warfarin.	zero to 10 weeks
Area under the effect-time curve from time zero to the last measurable concentration (AUEC(0-last)) of international normalized ratio (INR) of warfarin.	zero to 10 weeks

Collaborators and Investigators

• Sponsor: Intarcia Therapeutics

Study record dates

Study Major Dates

• Study Start: December 1, 2015
• Primary Completion (Actual): March 1, 2016
• Study Completion (Actual): March 1, 2016

Study Registration Dates

• First Submitted: December 21, 2015
• First Submitted That Met QC Criteria: December 24, 2015
• First Posted (Estimate): December 30, 2015

Study Record Updates

• Last Update Posted (Estimate): January 27, 2017
• Last Update Submitted That Met QC Criteria: January 26, 2017
• Last Verified: January 1, 2017

More Information

Terms related to this study

• Keywords: Adult; Volunteers; Female; Male
• Additional Relevant MeSH Terms: Hypoglycemic Agents; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Arrhythmia Agents; Antihypertensive Agents; Peripheral Nervous System Agents; Enzyme Inhibitors; Analgesics; Sensory System Agents; Analgesics, Non-Narcotic; Antipyretics; Antimetabolites; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Protease Inhibitors; Protective Agents; Cardiotonic Agents; Anticholesteremic Agents; Hypolipidemic Agents; Lipid Regulating Agents; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Anticoagulants; Anti-Obesity Agents; Incretins; Angiotensin-Converting Enzyme Inhibitors; Digoxin; Atorvastatin; Acetaminophen; Warfarin; Exenatide; Lisinopril
• Other Study ID Numbers: ITCA 650-CLP-115

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO